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Abstract
Oral preexposure prophylaxis (PrEP) trials report disparate efficacy attributed to variable adherence. HPTN 066
was conducted to establish objective, quantitative benchmarks for discrete, regular levels of adherence using
directly observed dosing of tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC). Healthy, HIV-
uninfected men and women were randomized to one of four oral regimens of fixed-dose TDF 300 mg/FTC 200 mg
tablet for 5 weeks with all doses observed: one tablet weekly (one/week), one tablet twice weekly (two/week), two
tablets twice weekly (four/week), or one tablet daily (seven/week). Trough serum TFV and FTC, peripheral blood
mononuclear cell (PBMC), and CD4+ TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) concentra-
tions were determined throughout dosing and 2 weeks after the last dose. Rectosigmoidal, semen, and cervi-
covaginal samples were collected for drug assessment at end of dosing and 2 weeks later in a subset of
participants. The 49 enrolled participants tolerated the regimens well. All regimens achieved steady-state con-
centrations by the second dose for serum TFV/FTC and by 7 days for PBMC TFV-DP/FTC-TP. Steady-state
median TFV-DP predose concentrations demonstrated dose proportionality: one/week 1.6 fmol/106 PBMCs, two/
week 9.1, four/week 18.8, seven/week, 36.3. Further, TFV-DP was consistently quantifiable 2 weeks after the last
dose for the ‡4/week regimens. Adherence benchmarks were identified using receiver operating characteristic
curves, which had areas under the curve ‡0.93 for all analytes in serum and PBMCs. Intersubject and intrasubject
coefficients of variation (%CV) ranged from 33% to 63% and 14% to 34%, respectively, for all analytes in serum
and PBMCs. Steady-state PBMC TFV-DP was established earlier and at lower concentrations than predicted and
was the only analyte demonstrating predose concentration dose proportionality. Steady-state daily dosing serum
TFV and PBMC TFV-DP was consistent with highly effective PrEP clinical trials. HPTN 066 provides adherence
benchmarks for oral TFV/FTC regimens to assist interpreting study outcomes.
Introduction
Randomized clinical trials of HIV preexposure pro-phylaxis (PrEP) have demonstrated the efficacy of daily
oral tenofovir disoproxil fumarate (TDF)-containing regi-
mens in high-risk individuals.1–4 While proven, PrEP effi-
cacy has been highly variable, showing a relative risk
reduction of HIV acquisition of 44% in men who have sex
with men (MSM) and transgender women (TGW) (iPrEx),2
62% in heterosexual men and women (TDF2),4 67–75% in
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heterosexual serodiscordant men and women (Partners-
PrEP),1 and 49% in people who inject drugs (Bangkok
TDF).3 In contrast, two other PrEP studies (FEM-PrEP and
VOICE) showed a lack of efficacy of PrEP in women.5,6
Notably, HIV seroconversion variability within and among
randomized controlled trials of PrEP has largely been at-
tributed to medication adherence.1,2,5,7–10 With the impact of
adherence on efficacy and the emerging investigation of less
than daily dosing regimens, quantitative measures that ac-
curately assess adherence in a variety of PrEP dosing sce-
narios are essential.
PrEP trials have employed a variety of adherence mea-
sures, each with limitations.11 Self-report is limited by recall,
overreporting, and social desirability biases. Pill counts,
pharmacy records, and medication event monitoring systems
may improve adherence data accuracy as compared to self-
report, but do not record the actual dose-taking event. Using
drug concentrations to assess adherence circumvents the re-
search participant’s ability to manipulate these other mea-
sures and provides evidence of dose taking; however, it
requires differentiating the influence of variable adherence
from variable pharmacokinetic influences, e.g., by drug half-
life, food and drug interactions, genetic variations, and dos-
ing regimen.12 These variables provide substantial challenges
in establishing and interpreting quantitative adherence as-
sessments. Therefore, understanding interindividual and
intraindividual variability is important to adherence assess-
ments using drug concentration.
The use of drug concentrations as a quantitative adherence
measurement requires understanding the relationship between
the dosing history and resulting drug concentrations. Estab-
lishing dose-concentration proportionality for a given pharma-
cologic measure makes it possible to make simple proportional
assessments of adherence from drug concentrations. However,
dose proportionality is traditionally assessed using peak con-
centration (Cmax) and area under the concentration-time curve
(AUC) and these parameters are a challenge to capture in a
randomized controlled trial. However, a drug with a long half-
life relative to its dosing interval varies little in concentration
within a dosing interval. In this special case, the timing of
sample collection has little impact on drug concentration and the
recent pattern of actual dose taking remains the most influential
modifier of random drug concentration.
The dose proportionalities of Cmax and AUC plasma
tenofovir (TFV) and emtricitabine (FTC) are well-
established,13,14 but not practical in randomized controlled
trials. Furthermore, because plasma TFV and FTC have half-
lives shorter than a daily dosing interval, random drug con-
centrations are not expected to be dose proportional and they
poorly reflect recent dose-taking patterns quantitatively.
Conversely, the dose proportionality of the active phos-
phorylated drug form of emtricitabine, emtricitabine-
triphosphate (FTC-TP), has yet to be determined in a healthy
PrEP population. The half-lives of these phosphorylated drug
forms may be long enough that drug concentration through-
out a daily dosing interval may be sufficiently stable to
demonstrate proportionality between dose frequency and
drug concentration, therefore, increasing their utility in as-
sessing adherence15 in a randomized clinical trial setting.
We performed a pharmacokinetic (PK) study of four dosing
regimens of the fixed dose tablet of oral TDF/FTC under direct
observation to remove adherence as an experimental variable.
Our objective was to describe 100% adherence benchmarks for
a range of dose-taking frequencies of oral TDF/FTC in healthy
volunteers, evaluate dose proportionality, and describe drug
concentration variability at steady state to interpret drug con-
centration as a quantitative adherence measure in a PrEP trial
setting. We also characterized the safety profiles of the four
different dosing regimens.
Materials and Methods
HPTN 066 was a two-site, open label, randomized, four-
arm PK study of TFV, FTC, and their active phosphorylated
metabolites in various body compartments following directly
observed dosing of fixed-dose, combination tablets of TDF/
FTC (Truvada Gilead Sciences, Foster City, CA). All par-
ticipants provided written informed consent prior to any
study procedures. The study protocol was approved by the
Institutional Review Boards at the University of North Car-
olina, Chapel Hill and The Johns Hopkins University (Clin-
icalTrials.gov Identifier: NCT01276600). The consort flow
diagram is provided in Fig. 1.
Study participants and procedures
Eligible participants were sexually active HIV-negative
healthy men and nonpregnant, nonbreast-feeding, and pre-
menopausal women aged 18–44 years. Volunteers were re-
cruited from the community surrounding the University of
North Carolina, Chapel Hill and The Johns Hopkins Hospital
in Baltimore, MD. Racial/ethnic categories were based on
self-identification. Participants were screened for protocol
eligibility based on history and physical, hematology, serum
chemistry, urinalysis for proteinuria and glycosuria, coagu-
lation panel, HIV and other sexually transmitted diseases, and
hepatitis B surface antigen testing.
By protocol, 32 research participants were to be random-
ized 1:1:1:1 to one of four dosing regimens of oral Truvada
(FTC 200 mg-TDF 300 mg) for nearly 5 weeks (35 days):
Arm 1, one tablet orally once weekly (one/week); Arm 2, one
tablet orally twice weekly (two/week); Arm 4, two tablets
orally twice weekly (Monday and Thursday, four/week); and
Arm 7, one tablet once daily (seven/week) (Fig. 2). Regard-
less of regimen, all doses, including weekends, were taken
under direct face-to-face observation and documented by
study personnel. Doses were taken without regard to food. By
design, within each dosing regimen, four participants agreed
to participate in the tissue-fluid sampling cohort and four
were assigned to the blood only cohort. Blood only cohort
participants had PK sampling only for blood; tissue-fluid
cohort participants had additional biopsies and body fluid
collections sampled on day 35 and day 49. Men and women
were apportioned evenly in all regimens and in both the
tissue-fluid and blood only cohorts. Evaluability for PK
analysis required complete collection of all planned matrices
at days 28 and 35 (a priori assumed to represent a steady-state
defining concentration pair) and day 49 (multiple half-life
TFV-DP decay time). These criteria were revised post hoc to
be more inclusive (see Results).
PK sampling
PK sampling of blood for serum and peripheral blood
mononuclear cells (PBMCs) occurred at enrollment, prior to
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the second dose, prior to the scheduled dose on days 7, 14, 21,
and 28, 24 h after the last dose (day 34) on day 35, and 2
weeks after the last dose on day 49. Per protocol, half of the
participants in each treatment group were to undergo addi-
tional tissue-fluid sampling on days 35 and 49. Samples from
men in the tissue-fluid cohort included rectal tissue (biopsy)
and fluid (sponge via anoscopy) and self-collected semen
(ejaculation), while samples from women were composed of
vaginal tissue (biopsy) and cervicovaginal fluid (direct as-
pirate), followed by rectal tissue and fluid as in the men.
Dosing and sampling for 5 weeks were selected to ensure
achievement of at least two observations at steady state for
PBMC TFV-DP estimated a priori to be day 28 and day 35
based on a TFV-DP half-life in HIV-infected patients of
*150 h based on prior reports.15–17
PK sample processing
For blood processing in all participants, serum was pre-
pared by centrifugation of coagulated blood in serum sepa-
rator tubes at 1,500 · g for 10 min at 4C, aliquoted into
cryovials, and stored at -80C until analysis. PBMCs were
isolated via centrifugation of a cell preparation tube (CPT) at
1,800 · g for 20 min at ambient temperature (20–25C),
collected from the buffy coat, washed once with phosphate-
buffered saline (PBS), and centrifuged at 400 · g for 15 min
at 4C. Cells were resuspended in 10 ml PBS for cell count-
ing. The cells were centrifuged again at 400 · g for 15 min at
4C. Cell pellets were lysed with 2 ml of 70% ice cold
methanol in water and stored at -80C until analysis.
For tissue-fluid cohort sample processing, rectal fluid was
collected in a preweighed container using a sponge (Merocel
eye-wick spears, Fisher Scientific #NC0093269) via a 4-cm
anoscope, reweighed after sample collection, and stored at
-80C until analysis. Vaginal fluid was collected via direct
aspiration using a specialized syringe (UNC CFAR Vaginal
specimen aspirator) as previously published following which
the sample was placed in a preweighed cryovial and subse-
quently reweighed and stored at -80C.18,19 After liquefac-
tion (within 30 min), semen was centrifuged at 600–800 · g
for 10 min at 4C, and supernatants were aliquoted and stored
-80C. Colon biopsies were collected via flexible sigmoid-
oscopy using 3.7-mm pinch biopsy forceps (Microvasive no.
1599; Boston Scientific Corp., Natick, MA) 10–20 cm from
the anus. Vaginal biopsies were collected by direct visuali-
zation following speculum insertion. Up to five vaginal bi-
opsies were taken with 2.3 · 4.2-mm Tischler gold-plated
gynecological forceps.
FIG. 1. Research partici-
pant disposition
FIG. 2. Study sampling schema. Study phases are indicated across study days from 0 to 49 as planned: Accumulation (day
0–28), Steady-State (day 28–35), and Decay (day 35–49). Up pointing gray arrows indicate all sampling is predose except
for terminal day 49 sampling, which occurs 2 weeks after the last dose (day 35). Pharmacokinetic (PK) sampling of blood
[serum, peripheral blood mononuclear cells (PBMCs), CD4+ cells)] occurs similarly for all subjects except for the presecond
dose sample that occurs uniquely for more than weekly frequency regimens (light gray arrows) on day 2 (daily regimen)
and day 3 (twice weekly regimens). Tissue-fluid cohort sampling is indicated by black arrows (days 35 and 49 only).
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Biopsies were placed in RPMI medium with l-glutamine
and 10% fetal bovine serum (R10 media) until processing.
Biopsies for homogenate were weighed and homogenized at
room temperature with 0.5 ml of 70% ice cold methanol using
the disposable pestle and cordless motor (VWR) for 2 min.
Samples were spun in a microcentrifuge, 4C, 14,000 · g for
10 min. Samples were immediately frozen at -80C. To re-
lease colon and vaginal tissue cells for intracellular drug
analysis, biopsies were incubated with an enzyme cocktail
(collagenase type II, DNase I, elastase, and hyaluronidase) in
RPMI containing l-glutamine, HEPES, and 7.5% fetal bo-
vine serum (FBS) in 50-ml conical tubes at 37C with agi-
tation (Invitrogen, Carlsbad, CA), as previously described.20
Cells were counted via the Guava/Millipore EasyCyte Plus
(Millipore, Billerica, MA). CD4+ cells were isolated via
positive selection with CD4+ microbeads using magnetic
affinity column separation according to the manufacturer’s
recommended protocol (Miltenyi Biotec, Auburn, CA).
Thereafter, cells were processed similarly to the PBMCs as
described above.
Drug concentration analysis
TFV, FTC, TFV-DP, and FTC-TP concentrations were
determined by previously described liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) methods vali-
dated for each biological matrix of origin by the Johns
Hopkins Clinical Pharmacology Analytical Laboratory
(CPAL) and the Colorado Antiviral Pharmacology Labora-
tory (CAVP).21–23 Both laboratories participate in the Na-
tional Institutes of Health-supported Clinical Pharmacology
Quality Assurance (CPQA) program of assay method exter-
nal review and approval and periodic proficiency testing for
TFV and FTC in plasma.24 All assays were validated based
on the recommendations of the Food and Drug Administra-
tion Guidance for Industry, Bioanalytical Method Validation
and met all acceptability criteria. Validation metrics included
precision, accuracy, stability, and matrix effects.
Briefly, thawed aliquots of serum and tissue homogenate,
with 13C5-TFV and
15N2
13C – FTC internal standards (IS),
were protein precipitated with methanol. Analytes of interest
from CVF, rectal fluid, and semen aliquots were isolated
using Oasis MCX 30-lm solid phase extraction plates (Wa-
ters Corporation, Milford, MA). Extracted eluants were col-
lected, dried, and reconstituted in 0.5% acetic acid in water
for analysis. Samples underwent chromatographic separation
using gradient elution with a reversed phase C18 column on
an Acquity UPLC system (Waters), and the dual detection of
TFV and FTC was performed using an API 4000 tandem
mass spectrometer (AB SCIEX, Foster City, CA), with an ESI
source operated in positive ionization mode. Analytes were
monitored in selective reaction monitoring mode. The analytical
measuring ranges (primary linearity) for the assays are as fol-
lows: serum TFV: 0.31–1,000 ng/ml, FTC: 0.31–5,000 ng/ml,
CVF TFV: 5–1,280 ng/ml, FTC: 20–5,120 ng/ml; rectal fluid
TFV: 1.25–320 ng/sponge, FTC: 5–1,280 ng/sponge; seminal
plasma TFV: 25–1,000 ng/ml, FTC:5–5,000 ng/ml; tissue TFV:
0.05–50 ng/sample (median LLOQ based on biopsy weights,
colon 0.01 ng/mg, vagina 0.02 ng/mg), FTC: 0.25–250 ng/
sample (median colon 0.04 ng/mg, vagina 0.08 ng/mg).
Tissue cell lysates and homogenates for TFV-DP quanti-
tation were analyzed using an indirect assay measuring TFV
in the sample after isolation of TFV-DP and enzymatic
conversion to TFV, as previously described.22 TFV-DP was
isolated from cell lysates on a Waters QMA cartridge (Waters
Corporation, Milford, MA) over a KCl gradient, enzymati-
cally dephosphorylated to TFV via sweet potato phosphatase
digestion with 13C5-TFV internal standard. Desalted sample
eluants were dried and reconstituted in 0.5% acetic acid in
water for analysis. Samples were analyzed using a reversed
phase C18 column as described on a Water Acquity UPLC
system interfaced with an API 5000 mass spectrometer. The
assay is linear over the range of 50–1,500 fmol TFV-DP/
sample. TFV-DP and FTC-TP concentrations in lysed PBMC
matrix were assayed with a validated LC-MS/MS method as
described previously.22 The dynamic range was 2.5–
2,000 fmol/sample for TFV-DP and 0.1–200 pmol/sample for
FTC-TP. Five million PBMCs were typically assayed per
PBMC sample resulting in an LLOQ of 0.5 fmol/106 cells for
TFV-DP and 0.02 pmol/106 cells for FTC-TP.
Pharmacokinetic and statistical analysis
Adverse event frequency across study regimens was as-
sessed using a chi-square test. Concentrations at each time
point were summarized using descriptive statistics. Dose
proportionality was assessed across study regimens using
dose-adjusted predose concentrations (Cs) for each day of
observation through day 35: the Kruskal–Wallis test was used
to test for equality of these dose-adjusted concentrations.
[Note: Because of several outliers and small sample size
within each dosing arm (9 to 13 participants), the nonpara-
metric Kruskal–Wallis test was used.] For observation times
with statistically significant differences, pairwise compari-
sons between study regimens were then tested using Wil-
coxon rank sum tests with post hoc corrections (Bonferroni).
Time to steady state was assessed by nonparametric ANOVA
within a dose cohort among all observation times. Statisti-
cally significant differences were further tested for differ-
ences between consecutive sampling times using paired
Wilcoxon rank sum tests with post hoc corrections (Bonfer-
roni). To assess dose accumulation, the concentration prior to
the second dose was compared (paired Wilcoxon rank sum
test) to each of the subsequent steady-state predose concen-
trations for each individual. Total cell to CD4+ cell TFV-DP
and FTC-TP ratios were tested for statistical significance
using the one sample Wilcoxon signed rank test. Bivariate
parameter correlations between drug analyte-matrix pairs
were tested using the Spearman rank correlation test.
The terminal half-life for TFV-DP was estimated based on
the PBMC sample collected 24 h after the final dose. This
steady-state terminal half-life estimate was compared to an
estimate based on superposition of 28 daily single doses
based on the single dose TFV-DP concentration–time profile
reported in Louissaint, et al. and Chen, et al., as reported
subsequent to the design of HPTN 066, both of which indi-
cate TFV-DP peaks occurring over a 3- to 4-day period prior
to beginning its terminal decay.20,25 Intersubject variability
was calculated from the percent coefficient of variation
(%CV) for all subjects within a given sample day and re-
ported as median (range) from among all steady-state sample
times (D7 through D35) CV%s. Intrasubject variation was
calculated from the CV% for each subject across all steady-
state sample days (D7 through D35) and reported as median
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(range) from among all subjects CV%s. For all comparison
tests, p-values £0.05 were considered statistically significant.
Receiver operating characteristics curves were explored to
select concentration thresholds for each dose frequency and
each matrix-analyte pair. All steady-state concentrations (day
7 to day 35) were pooled in this analysis. Statistical signifi-
cance was evaluated using area under the curve and 95%
confidence interval. Threshold concentrations optimized for
greater than 90% sensitivity and for greater than 90% spec-
ificity were selected based on the ROC analysis. Generalized
estimating equations (GEE) were also used for this analysis
given the repeated measures in multiple individuals (SAS
version 13.2, SAS Institute, Cary, NC).
Results
Demographics, disposition, adverse events
Forty-nine participants were enrolled for which adverse
event data are reported (safety cohort). Baseline demo-
graphics were comparable between the four treatment regi-
mens (Table 1). There were no differences in baseline values
between the tissue-fluid and blood only cohort. Forty-five
research participants were evaluable for PK assessments (PK
cohort). Of the four participants not evaluable for PK as-
sessments, all refused further participation at some point
during the study for a variety of reasons (refused to continue
after randomization to daily DOT, incarceration, spouse de-
mands, family member health demands on time). The PK
cohort was composed of the originally planned 32 partici-
pants plus 13 additional participants. Ten were replacement
participants necessitated by compromised PBMC samples in
the original cohort since PBMC TFV-DP and FTC-TP con-
centration informed critical study endpoints. Three additional
individuals were initially determined not to be evaluable by
protocol, but were later included in the PK analysis based on
reevaluation of inclusion criteria in light of study data that
differed greatly from a priori expectations.
Briefly, because TFV-DP half-life in healthy subjects was
far below the value in HIV-infected patients (see below) (1)
time to steady-state concentration occurred far sooner (day
7), thus making day 28 and day 35 less essential, and (2) time
to undetectable TFV-DP concentrations after cessation of
dosing occurred far sooner than expected. These observations
rendered analysis of TFV-DP concentrations at day 49 far
less important. Accordingly, the study team agreed to include
three individuals. All research clinic doses given were ob-
served by study personnel.
All dosing regimens were well tolerated. A total of 58
adverse events (AEs) occurred in 32 (65%) of the 49 par-
ticipants and were all mild or moderate in severity; 55% of
these AEs were attributed to study drugs. There were no
serious AEs. Regardless of attribution, the most frequent AEs
were nausea and/or vomiting (10%), musculoskeletal pain
(9%), headache (7%), fatigue (7%), hypophosphatemia (9%),
anemia (5%), lower gastrointestinal disturbance (5%), and
skin disorders (5%), with all other AEs occurring in less than
5% of research participants. There was no association be-
tween dosing regimen and AE frequency ( p > 0.05).
Tenofovir serum and PBMC pharmacokinetics
Concentration–time profiles for TFV, PBMC TFV-DP,
and PBMC CD4+ TFV-DP in the four treatment regimens
(Fig. 3A) all indicate a rise to, and achievement of, plateau
concentrations by the first week on drug (day 7); plateau
prodrug or metabolite concentrations were maintained for 5
weeks (day 35); following the last dose, concentrations fell
toward and often below the lower limits of assay quantifi-
cation. TFV in serum and TFV-DP in PBMCs reached steady
state within 7 days in the daily cohort. In less frequent dosing
cohorts, differences between predose concentrations for the
second dose and the first weekly observation was significant
only for serum TFV and not TFV-DP. TFV-DP in blood
CD4+ cells was not different between any sample times
within any dose frequency arm. Among TFV analytes, the
steady-state trough concentration (Css) was greater than the
single dose trough concentration (Cs,1) only for serum TFV
and PBMC TFV-DP in the daily dosing cohort [Cs,ss/Cs,1
median (IQR) among individual medians, 1.6 (1.5, 1.6) and
4.8 (4.5, 5.2), respectively] and for PBMC CD4+ cells in both
the four/week arm [2.4 (2.1, 2.7)] and daily arm [8.9 (7.9,
9.2)]; these observations are indicative of drug accumulation.
The typical serum TFV Cs values across 5 weeks (median
of each of five weekly medians) indicate a disproportionate
increase when transitioning from four doses weekly to daily
dosing (Table 2A). In contrast, typical Cs PBMC TFV-DP
increased proportionally with increasing dose frequency
from weekly to daily dosing. PBMC CD4+ cell subsets at
steady state were dose proportional four of five study weeks
(only Arm 1 was not dose proportional with the other arms in
that week). Based on statistical analyses of dose-adjusted Cs,
Table 1. Demographic Characteristics
Arm 1 Arm 2 Arm 4 Arm 7
Dose frequency 1 tab 1·/wk 1 tab 2·/wk 2 tabs 2·/wk 1 tab daily
Number of participants 9 12 13 15
Age, median years (IQR) 30 (25–36) 25 (22–35) 32 (27–39) 31 (24–37)
Gender, n (%)
Male 4 (44) 6 (50) 5 (38) 5 (33)
Female 5 (56) 6 (50) 8 (62) 10 (67)
Race, n (%)
Asian 1 (11) 0 (0) 0 (0) 0 (0)
Black 3 (33) 5 (42) 7 (54) 8 (53)
White 4 (44) 5 (42) 6 (46) 6 (40)
Other 1 (11) 2 (17) 0 (0) 1 (7)
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FIG. 3. (A) Tenofovir analyte predose median (IQR) concentration vs. time relationships for all dosing regimens: one
tablet weekly, red triangle; one tablet, two times per week, green square; two tablets twice weekly, blue diamond; one
tablet daily, gold circle. (B) Emtricitabine moiety predose median (IQR) concentration vs. time relationships for all dosing
regimens: one tablet weekly, red triangle; one tablet, two times per week, green square; two tablets twice weekly, blue
diamond; one tablet daily, gold circle.
Table 2A. Steady-State Tenofovir Pharmacokinetic Summary by Analyte and Location
Matrix Analyte TFV LLOQa Arm 1 Arm 2 Arm 4 Arm 7
Dose frequency 1 tab 1·/wk 1 tab 2·/wk 2 tabs 2·/wk 1 tab daily
Serumb TFV 0.31 ng/ml 0.5 (0.5–0.6) 3.6 (2.6–3.7) 5.9 (4.6–6.4) 52.2 (49.0–55.6)
PBMC totalb TFV-DP 0.5 fmol/106 cells 1.6 (BLQc–2.9) 9.1 (6.3–11.0) 18.8 (14.5–20.4) 36.3 (29.0–38.5)
PBMC CD4+ onlyb TFV-DP 0.5 fmol/106 cells 1.7 (BLQ–18.7) 4.0 (BLQ–91.2) 14.6 (7.8–100.6) 24.1 (0.4–117.8)
Colon homogenated TFV 0.01 ng/mge 0.02 (0.01–0.10) 0.23 (0.05–3.28) 1.58 (0.21–4.75) 5.42 (0.21–20.54)
Colon homogenated TFV-DP 5 fmol/mge 16 (BLQ–21) 27 (13–762) 186 (58–412) 206 (0–595)
Colon total cellsd TFV-DP 0.5 fmol/106 cells 37 (2–122) 40 (0.6–84.7) 64 (BLQ–277) 160 (18–340)
Vagina homogenated TFV 0.02 ng/mge BLQ, BLQ BLQ, BLQ, BLQ BLQ, BLQ 0.02, 0.18
Vagina homogenated TFV-DP 5 fmol/mge BLQ, BLQ BLQ, BLQ BLQ, BLQ BLQ, 41
Vagina total cellsd TFV-DP 0.5 fmol/106 cells BLQ, 1038 BLQ, BLQ BLQ, 5.7 BLQ, BLQ
Rectal fluidd TFV 1.25 ng/sponge 3.7, 6.8 BLQ 25.8 1617
Cervicovaginal fluidd TFV 5 ng/ml 126 BLQ, 127 18, 77 625, 6290
Semend TFV 25 ng/ml BLQ, BLQ BLQ,BLQ 34, 98 409, 877
aLLOQ, lower limit of assay quantitation.
bMedian (range) of individual research participant medians at steady state (day 7–day 35).
cBLQ, below limit of assay quantitation. (Note: sample mass varies greatly, especially for tissue and tissue cells, with substantial impact
on true assay sensitivity.)
dMedian (range) of day 35 concentrations; when three or fewer are available, all values are shown without parentheses.
eFor tissue homogenates, values are reported as ‘‘per mg’’ based on conversion from ‘‘per sample’’ divided by sample weight. LLOQ per
mg is based on median of sample weight and LLOQ per sample calculated for each sample.
TFV, tenofovir; TFV-DP, tenofovir diphosphate.
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serum TFV was not dose proportional in any week through-
out the study, which is as expected for trough concentrations
( p < 0.05). PBMC TDV-DP was dose proportional for all, but
one, sampling time (day 14) across treatment regimens.
PBMC CD4+ cells were dose proportional at all times.
Two weeks after the final dose, day 49, serum TFV con-
centrations were below the LLOQ (BLQ) in all arms, except for
two of eight (25%) in the four/week arm and four of 10 (40%)
in the daily arm [median (IQR), BLQ (BLQ, 0.36)]. For PBMC
TFV-DP, the median (IQR) was above LLOQ in seven of eight
of the four/week participants [median (IQR) 2.54 (1.43, 4.48)]
and eight of 10 daily arm participants [4.98 (1.75, 6.34)]. TFV-
DP in the two and one dose per week cohorts was two of 10 and
one of eight, respectively. The TFV-DP concentration in
PBMC was greater than in the CD4+ subsets with a median
(IQR) PBMC/CD4+ ratio of 1.25 (0.4, 2.5) ( p < 0.001).
Between day 7 and day 35, median interindividual coef-
ficients of variation ranged from 33% to 82%, 50% to
121%, and 46% to 71% for serum TFV, PBMC TFV-DP, and
CD4+ TFV-DP Cs, respectively (Table 3). Interindividual
variability in TFV and TFV-DP Cs increased with less fre-
quent dosing. Compared to interindividual variability, in-
traindividual variability had a lower range of 17% to 34% in
the daily dosing and double-dose twice weekly (4·/week)
treatment regimens for serum and PBMC. Intrasubject and
intersubject drug concentration variabilities were similar for
CD4+ cells (13–65%).
Emtricitabine serum and PBMC pharmacokinetics
Similar to TFV moieties, concentration–time profiles for
serum FTC, PBMC FTC-TP, and PBMC CD4+ FTC-TP in the
four treatment regimens all achieved plateau concentrations
by the first week (day 7), maintained this concentration for the
rest of the dosing period (through day 35), then decayed near
to or below assay quantification limits by day 49 (Fig. 3B).
Table 2B. Steady State Emtricitabine Pharmacokinetic Summary by Analyte and Location
Matrix Analyte FTC LLOQa Arm 1 Arm 2 Arm 4 Arm 7
Dose frequency 1 tab 1·/wk 1 tab 2·/wk 2 tabs 2·/wk 1 tab daily
Serumb FTC 0.31 ng/ml 0.8 (0.4–0.9) 5.4 (3.7–6.0) 6.7 (5.4–7.6) 70.9 (67.7–81.9)
PBMC totalb FTC-TP 0.02 pmol/106 cells 0.1 (0.1–0.1) 0.4 (0.2–0.5) 0.6 (0.5–0.6) 2.2 (1.5–2.6)
PBMC CD4+
onlyb
FTC-TP 0.02 pmol/106 cells 0.1 (0.1–1.7) 0.5 (0.1–6.5) 1.0 (0.3–6.9) 3.2 (0.1–12.3)
Colon
homogenatec
FTC 0.04 ng/mgd 0.13 (BLQe–0.21) 0.49 (0.20–2.08) 1.22 (0.36–5.74) 20.5 (1.87–49.32)
Colon total cellsc FTC-TP 0.5 fmol/106 cells BLQ (BLQ–BLQ) BLQ (BLQ–1.2) BLQ (BLQ–6.6) BLQ (BLQ–0.14)
Vagina
homogenatec
FTC 0.08 ng/mg BLQ, BLQ BLQ, BLQ, 0.38 BLQ, 0.14 3.02, 3.31
Vagina total cellsc FTC-TP 0.5 fmol/106 cells BLQ, BLQ BLQ, BLQ BLQ, BLQ BLQ, BLQ
Rectal fluidc FTC 5 ng/sponge BLQ,BLQ BLQ BLQ 20.8
Cervicovaginal
fluidc
FTC 20 ng/ml 124 BLQ, 182 143, 145 2330, 7420
Semenb FTC 5 ng/ml BLQ, 7.4 21, 23 13, 27 907, 992
aLLOQ, lower limit of assay quantitation.
bMedian (range) of individual research participant medians at steady state (day 7–day 35).
cMedian (range) of day 35 concentrations; when three or fewer values are available, all values are shown without parentheses.
dFor tissue homogenates, values are reported as ‘‘per mg’’ based on conversion from ‘‘per sample’’ divided by sample weight. LLOQ per
mg is based on median of sample weight and LLOQ per sample calculated for each sample.
eBLQ, below limit of assay quantitation. (Note: sample mass varies greatly, especially for tissue and tissue cells, with substantial impact
of true assay sensitivity.)
FTC, emtricitabine; FTC-TP, emtricitabine triphosphate.
Table 3. Inter- and Intraindividual Variability
Plasma TFV Plasma FTC PBMC TFV-DP PBMC FTC-TP CD4+ TFV-DP CD4+ FTC-TP
Intersubject
1 tab 1·/wk 82 (77–92) 86 (82–105) 121 (85–171) 70 (50–88) 53 (46–92) 75 (52–91)
1 tab 2·/wk 41 (36–70) 49 (34–65) 61 (47–164) 78 (68–193) 46 (26–52) 64 (52–87)
2 tabs 2·/wk 60 (42–63) 48 (32–99) 49 (32–59) 54 (44–67) 51 (29–63) 53 (26–58)
1 tab daily 33 (30–49) 33 (28–54) 50 (33–66) 63 (54–81) 71 (24–87) 62 (25–86)
Intrasubject
2 tabs 2·/wk 24 (10–78) 18 (7–70) 23 (18–79) 25 (10–74) 16 (1–63) 13 (5–66)
1 tab daily 17 (6–56) 14 (8–53) 34 (14–77) 32 (21–79) 55 (11–95) 65 (10–96)
Median (range) of CV% of steady state (day 7–day 35) values.
Intersubject variability calculated from CV% for all subjects within a given sample day; median (range) is from among D7, D14, D21,
D28, D35 CV%s.
Intrasubject variability calculated from CV% for each subject across all his or her steady-state samples days (D7–D35); median (range) is
from among all subjects CV%s. Only higher dose frequency is included due to predominance of BLQ values.
38 HENDRIX ET AL.
FTC in serum and FTC-TP in PBMCs reached steady state
within 7 days of dosing (Table 2). Fractional accumulation of
serum FTC at steady state seen in the daily dosing arm, 1.6
(1.5, 1.6), was similar in magnitude to serum TFV; daily
dosing PBMC FTC-TP accumulation at steady state, 1.8 (1.7,
1.8) was less than half the accumulation seen for PBMC TFV-
DP. There was no evidence of PBMC CD4+ cell accumulation
in any regimen.
All FTC analyte Cs values across 5 weeks failed to dem-
onstrate dose proportionality (all p < 0.05) with the daily
dosing arm being disproportionately larger than the less
frequent dosing cohorts (Table 2B). At week 49, the only
detectable analyte was FTC-TP in the daily dosing cohort
with seven of seven participant samples above the LLOQ,
median (IQR) 2.2 (1.5–2.6) pmol/106 cells. The FTC-TP
concentration in PBMCs was slightly more than half of the
concentration in CD4+ subsets with a median (IQR) PBMC/
CD4+ ratio of 0.58 (0.18, 0.96) ( p < 0.001).
Interindividual variability was similar to TFV moieties
across all treatment regimens with a range of 33–86% for
serum FTC, 54–70% for PBMC FTC-TP, and 53–75% for
CD4+ FTC-TP and increased with decreasing dosing fre-
quency. Intraindividual variability was 14–32% in the daily
dosing and double-dose twice weekly regimens for serum and
PBMCs. It increased to 65% in the daily dosing CD4+ samples.
Tissue-fluid sampling cohort
Where quantifiable, steady-state day 35 concentrations of
all analytes in nearly all matrices of the tissue-fluid sampling
cohort increased with increasing weekly cumulative dose
(Table 2). Many concentrations were not quantifiable, espe-
cially in infrequent dosing arms. All CD4+ cell subset data
were below the limits of quantification. Except for the vaginal
homogenate TFV and FTC concentrations with daily dosing,
nearly all vaginal samples were below quantitative limits.
Accordingly, dose proportionality was not tested. Of all
matrices, colon tissue and tissue cells for TFV and TFV-DP
and colon tissue homogenate for FTC-TP were the only
matrix–analyte combination consistently detectable for most
subjects in all treatment regimens. Concentrations of TFV
analytes, where quantifiable, were higher in colon tissue and
cells than in vaginal tissue and cells (except for a single TFV-
DP vaginal tissue cell value in the weekly cohort). FTC was
also greater in colon compared to vaginal tissue homogena-
tes. By day 49, concentrations were consistently detectable
(roughly half of participants) only in the four or seven dose
per week regimens and only for TFV and TFV-DP in colon
tissue homogenate and cells, semen, and CVF. At day 49,
FTC was detected in half or fewer of participants in colon
tissue homogenates in ‡2·/week groups and only in the daily
group in semen.
Intercompartment correlations
Serum TFV and FTC correlated with a high degree of
statistical significance ( p < 0.001) and relatively high corre-
lation coefficients [all r > 0.5 except PBMC CD4+ cells
(r > 0.24)] with all drug analytes assessed in all sites (where
values were quantifiable). Beyond serum, concentrations
were best correlated with the concentrations in an adjacent
anatomic compartment (e.g., serum with PBMC or total cells
with CD4+ cells) or parent and active drug in a given com-
partment, for example, TFV with TFV-DP in colon tissue
homogenate (r = 0.87, p < 0.001) and PBMC and colon TFV-
DP (r = 0.62, p < 0.001) and FTC-TP (r = 0.832, p < 0.001).
The notably absent correlations were between vaginal tissue
TFV, TFV-DP, and FTC and any other drug-matrix sample
type where no correlations outside vaginal tissue were sta-
tistically significant, though these were correlated with each
other (r = 0.55, p = 0.03). Vaginal tissue FTC-TP was not
assessed. There were no statistically significant correlations
between creatinine or creatinine clearance and serum TFV or
FTC Cs concentrations. There were no statistically significant
gender differences in any blood or colon tissue or fluid pa-
rameters.
ROC and adherence threshold analysis
ROC analysis of all pooled steady-state observations in-
dicates an excellent ability to discriminate between adher-
ence levels based on ROC curves (Fig. 4) and a high AUC for
all analytes (TFV, TFV-DP, FTC, FTC-TP) and matrices
(plasma, PBMCs, PBMC CD4+ cells). AUC values ranged
from 0.93 to 1.00 for all analytes in plasma and PBMCs.
PBMC CD4+ cells were a little lower, from 0.81 to 0.94.
Threshold concentrations indicating a minimum number of
doses per week or greater were selected to optimize for
FIG. 4. Receiver operating
characteristic (ROC) curves
for plasma tenofovir (TFV)
(left) and PBMC TFV-DP
(right). The legend for each
figure indicates the dose fre-
quency ranging from one to
seven doses per week and the
associated area under the
curve (AUC) for the ROC
curve.
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sensitivity greater than 90% and specificity greater than 90%
(Supplementary Table S1; Supplementary Data are available
online at www.liebertpub.com/aid). For example, selecting
thresholds to be inclusive, by optimizing for greater than or
equal to 90% sensitivity, plasma TFV concentrations of at
least 35.5, 4.2, 2.5, and 0.5 ng/ml or PBMC TFV-DP con-
centrations of 16.8, 9.9, 5.2, and 1.6 fmol/106 cells indicate
adherence consistent with at least seven, four, two, and one
dose in the prior week, respectively. Strictly controlling for
repeated measures in a given individual with a GEE analysis
yielded highly concordant results with those reported above,
which pooled 5 weeks of observations from among all
subjects.
Discussion
We describe the concentrations of serum TFV and FTC
and PBMC TFV-DP and FTC-TP in four dosing regimens
using directly observed TDF/FTC dosing to establish 100%
adherence benchmarks for dose taking ranging from weekly
to daily. The finding of dose proportionality for TFV-DP
allows for the simple proportional extrapolation of TFV-DP
concentration to estimate adherence (e.g., 50% adherence
would yield 50% the expected 100% benchmark). While the
precision of such estimates is limited on an individual basis
due to the large interindividual variability compared to serum
concentrations, the relatively smaller intraindividual vari-
ability allows improved precision in adherence estimates if
baseline PK data, after an observed dose, are available.12,23,26
In a clinical study sample, absence of detectable PBMC TFV-
DP suggests no doses taken within the prior week, similar to
plasma or serum. This was an unexpectedly short period of
‘‘look back’’ due to a shorter TFV-DP half-life than expected.
For TFV, FTC, and FTC-TP, the lack of dose pro-
portionality for predose concentrations was anticipated based
on a shorter drug half-life relative to dosing interval com-
pared to TFV-DP in the less than daily dosing regimens. This
does not preclude the use of these moieties for adherence
assessment, but it indicates a greater sensitivity to timing of
doses on drug concentration, which complicates their use for
quantitative adherence assessment. Furthermore, due to the
shorter half-life of TFV and FTC in serum, drug concentra-
tion measurements have the capacity to reflect only recent
(several days) dosing compared to 1 week of dosing for
PBMC TFV-DP. From other reports, precise adherence pat-
tern estimates within an individual using plasma TFV are not
possible for even the prior 3 days.12
Despite these limitations, on a population basis, plasma
TFV predicts PrEP efficacy, given the close relationship
between plasma concentration, adherence, and efficacy.
More specifically, applying daily dosing steady-state serum
TFV concentration benchmarks from HPTN 066 to PrEP
clinical trials, we find median concentrations (1) consistent
with plasma concentrations reported in the Partners in Pre-
vention, CDC TDF2, and Bangkok PWID PrEP studies (high
levels of HIV protection), (2) higher than in iPrEx (moderate
protection), and (3) far higher than in FEM-PrEP and VOICE
(no protection).1–6 Furthermore, the combination of serum
TFV and PBMC TFV-DP data, given their different half-lives
and time to steady state (see below), makes it possible to
identify a white-coat effect—dosing only in the day(s) prior
to concentration assessment—by the combination serum or
plasma TFV concentration indicating dosing within the prior
day (>49 ng/ml) and PBMC TFV-DP indicating less than
daily dosing (<29 fmol/106 cells). White coat effect is im-
portant to exclude in interpreting therapeutic drug monitoring
data in clinical trials.27
Threshold concentrations associated with a discrete num-
ber of doses in the prior week serve as adherence benchmarks
when using pharmacologic measures to quantify recent ad-
herence in a study participant. Using an ROC assessment,
these pharmacologic measures are quite powerful in their
ability to discriminate among adherence levels. In addition to
describing the typical values (point estimates) associated
with each weekly dosing frequency, we used an ROC ap-
proach to provide benchmarks that are either more inclusive
(sensitivity optimized) or more stringent (specificity opti-
mized), depending on the use of the thresholds. Because our
sampling occurred at concentration troughs (predose) based
on precise dosing regimens and because there are many ways
to take four, two, or one pill in any prior week, the bench-
marks using shorter half-life plasma TFV, FTC, and FTC-TP
concentrations are more of an average from among a range of
possibilities. The long half-life of TFV-DP in PBMCs and
CD4+ cells is far more resistant to this effect.
Adherence benchmark values from this study may not
extrapolate to other studies where different sample proces-
sing and/or analytical procedures may be used. TFV-DP
values in this study are similar to values from several studies
in healthy volunteers,20,25,28 but are lower than values from
several other studies in both healthy volunteers29,30 and HIV-
infected patients.17,31,32 Additional investigation is required
to understand the reason for the differences in TFV-DP
among these studies. Until the differences are explained,
benchmarks will need to remain specific to the laboratory
performing the PBMC processing and PK sample analysis in
the benchmark study (e.g., HPTN 066, STRAND, and Cell-
PrEP) and the randomized controlled trial in which adherence
estimates are desired.
A major challenge of using drug concentrations as bio-
markers for adherence is the underlying interindividual and
intraindividual PK variability that also influences drug con-
centrations. To isolate PK-related variability, we eliminated
variability due to adherence through directly observed ther-
apy and characterized the intraindividual variability (CV%)
of serum and PBMC TFV-DP and FTC-TP as 17% to 34%
and 14% to 32%, respectively. These values will inform fu-
ture interpretation of drug concentration values and help
determine accurate sample size estimates for studies that use
drug concentration monitoring as an adherence measure.
The 7 days required to reach steady-state provides a cau-
tionary note when initiating periodic PrEP dosing regimens
given the delay in achieving protective concentrations. Based
on iPrEx protective concentrations (EC90), single daily oral
doses do not achieve these levels for 5 to 7 days; double doses
daily would be expected to achieve the iPrEx targets in less
time given the dose proportionality observed. Consistent with
our findings, the Cell-PrEP study reported that 89% of a
population would achieve iPrEx protective concentrations
after seven daily TDF/FTC doses.30 These time to protection
estimates, however, are applicable only to MSM/TGW since
dose frequency associated with high levels of protection in
women appear to be higher than in MSM. Furthermore, the
TFV-DP half-life in vaginal tissue cells is several times
40 HENDRIX ET AL.
longer than in colon tissue cells and would, therefore, take
longer to achieve protective levels even if protective tissue
concentrations were similar.20
The 7 day time to steady state of TFV-DP and the 5-fold
accumulation of TFV-DP at steady state are sooner and
lower, respectively, than the expected 3–4 week time to
steady state and 9-fold accumulation we anticipated based on
previous reports (which we used to design this study) in HIV-
infected individuals of an approximately 150 h terminal half-
life.15–17 Our findings are consistent with a 48–53 h TFV-DP
half-life that we reported in two prior studies. The first is a
single oral TDF dose study in healthy women using an ac-
celerator mass spectrometry analytical method and three
terminal concentrations over 2 weeks. The second is a mul-
tiple dose oral TDF study using a similar TFV-DP UPLC-
MS/MS analytical method as in HPTN 066 and a population
PK model-based estimation of TFV-DP half-life.20,26 Of
note, the PBMC TFV-DP terminal half-life could not be es-
timated directly in HPTN 066 using terminal half-life due to
the inability to use the penultimate day 35 data given the
sustained 3–4 day postdose PBMC TFV-DP plateau noted in
several recent reports.20,25,28 The plateau was not known at
the time HPTN 066 was designed and would bias the half-life
estimates upward.
The Cell-PrEP study reported that >90% of the TFV-DP
steady-state concentration was achieved after 12 daily doses
and 97% of FTC-TP steady-state was achieved after seven
daily doses.30 These values are internally consistent with
their reported 84 h half-life. The slightly longer time to TFV-
DP steady state in Cell-PrEP—12 daily doses vs. seven daily
doses in HPTN 066—may be related to the different study
design used. Specifically, HPTN 066 used paired compari-
sons of discrete sequential weekly observations to identify
the first week in which concentrations do not rise, therefore,
12 doses is not a possible outcome. Cell-PrEP modeled time
as a continuous variable and did not limit the analysis to
discrete week-long observation periods. Furthermore, given
the PK estimate variability reported in both HPTN 066 and
Cell-PrEP, we do not believe the numeric differences in time
to steady state are truly different.
We do not have a good explanation for the wide range in
absolute TFV-DP values (ranging from 36 to 160 fmol/106
cells) or differences in half-life estimates (ranging from 48 to
164 h) among studies.15–17,20,26 Some of this may be due to
variation in study design or pharmacokinetic modeling
methods as noted above. We do not have any suitable bio-
logical reasons to explain this apparent difference. Some
have suggested that the state of immune activation—higher
in some HIV+ patients compared to healthy uninfected
research participants—may account for the difference.
However, in vitro studies of phytohemagglutinin – interlukin-
2-stimulated PBMCs (surrogates for increased immune acti-
vation in HIV+ patients) show that TFV-DP is actually lower,
not higher, and consistent with a shorter half-life, when com-
pared to resting cells (surrogates for healthy volunteers).33,34
Furthermore, the longest and shortest PBMC TFV-DP half-life
studies are in healthy volunteers.20,35
In our tissue-fluid sampling cohort, steady-state TFV-DP
concentrations at day 35 were higher in colonic tissue ho-
mogenate than in vaginal tissue homogenate—a pattern de-
scribed in prior single dose studies, which sampled tissue at
24 h.20,36 Cell-specific TFV-DP differences are less clear due to
our many BQL results, which cannot necessarily be interpreted
as lower in concentration since fewer biopsies were available
for analysis from vaginal compared to colon tissue. However,
in a previous report, the colonic greater than vaginal tissue
homogenate differences were not seen in total cells extracted
from tissue.20 There were no differences in concentration be-
tween men and women for any drug moiety or location.
We did not sample at time points earlier than 1 week or
more frequently than weekly, so we could not evaluate
whether steady state had been achieved at an even earlier
time point (likely for FTC-TP). However, another study re-
ported a longer, not shorter, time to TFV-DP steady state.30
Because our primary outcomes were assessed using carefully
timed trough concentrations, our estimates are biased
downward for both concentration expectations for a given
dose frequency and variability compared to a clinical trial
context employing random sampling times. We did not per-
form frequent sampling of drug moieties to establish indi-
vidual PK parameters for these drug moieties. The
combination of individual PK parameters prior to or within a
clinical study would significantly improve the precision of
adherence estimates. The study is also limited by scarce data
in tissue and fluid samples, especially vaginal, which limits
precision and precludes evaluating tissue and fluid drug
concentrations as adherence benchmarks for these matrices.
This report highlights 100% adherence serum and
PBMC drug concentration benchmarks for weekly to daily
dose frequency of TDF/FTC, which is dose proportional
only for TFV-DP. A 1-week lead-in period of TDF/FTC
dosing is necessary to achieve steady-state concentrations
of TFV-DP and FTC-TP in PBMCs. Interindividual vari-
ability and intraindividual variability greatly differ de-
pending on the drug analyte being assessed. Threshold
concentrations for plasma and PBMC analytes differenti-
ate very well among various numbers of doses taken in the
prior week as surrogate for levels of adherence. These
results provide useful data for the design and interpretation
of future PrEP studies.
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